May 17, 2020

Pfizer to recover from set-back in the lung cancer drug market

Admin
3 min
Pfizer to recover from set-back in the lung cancer drug market.jpg
Written by Alyssa Clark As one of Americas largest and leanest pharmaceutical giants, Pfizer has continued to demonstrate its flexibility and producti...

Written by Alyssa Clark

 

As one of America’s largest and leanest pharmaceutical giants, Pfizer has continued to demonstrate its flexibility and productivity in foreign markets as well as domestically here in the U.S. Taking bold strides within the market over the past two years, this company has continuously tried to make itself even more valuable and marketable but branching into unpopular and unexplored markets. In an attempt to once and for all streamline their business and Pfizer has recently focused on the emerging oncology segment of the company in order to do so. However, things have not gone according to plan as Pfizer is now faced with reported failures of its leading lung cancer candidates and clinical tests.

The drug which was set to break into the lung cancer scene is named Dacomitinib, and was highly anticipated by investors and the market alike until it began reporting less than pleasing results. Dacomitnib works as an epidermal growth factor receptor tyrosine kinase inhibitor, or as it is more commonly referred to, an EGFR inhibitor. While in the experimental drug phase, the drug was eventually expected to put its non-small cell lung cancer competitors out of business. It is no secret that the competition, like Tarceva from Roche and Iressa from AstraZeneca and Teva, are no match for Pfizer’s proposed unique therapy which is technically irreversible and can act on multiple receptor types at once. However, with the recorded failures the trials have already shown, investors and the public are curious: how far will this set Pfizer back?

This new lung cancer drug was not expected to be as huge of a moneymaker as Pfizer’s number one grossing drug Lipitor, which was at one time the top selling drug in the world, but it definitely was not anticipated to be a major flop. In 2012, AstraZeneca and its partner earned an approximate $2 billion worldwide, setting the bar high for this experimental drug.

So how did this drug take such a turn for the worse? How did this drug have billion dollar companies worried, take a flop that could be detrimental to Pfizer’s 2014 growth?

Cory Renauer from the Motley Fool reports, “The problem with the drug wasn't safety or response rates, but long term survival. In the ARCHER 1009 trial, about 800 patients were given either Tarceva or dacomitinib. After 10 months the patients given dacomitinib did not show significant improvement in progression-free survival compared to patients that received Tarceva.

The answer in plain terms: the drugs improved short-term health, but in terms of long-term survival the drug recurrently failed. As stated before, the short-term results beat of Tarceva from Roche, thus accounting for the earlier promise associated with this new drug, but then when it was monitored over a 10-month period, the amount of patients who were administered Dacomitinib had a survival rate similar to those who took the placebo pills.

 “In the BR.26 trial, advanced lung cancer patients that had been treated previously with either Tarceva or Iressa, were given placebo or dacomitinib. At three and a half years, the overall survival rate of patients given dacomitinib was not significantly higher than those given placebo.”

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

AI
NHS
skincancer
Cancer
2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article